Identification of isobenzofuranone derivatives as promising antidiabetic agents: Synthesis, in vitro and in vivo inhibition of α-glucosidase and α-amylase, computational docking analysis and molecular dynamics simulations
- PMID: 38199537
- DOI: 10.1016/j.ijbiomac.2024.129241
Identification of isobenzofuranone derivatives as promising antidiabetic agents: Synthesis, in vitro and in vivo inhibition of α-glucosidase and α-amylase, computational docking analysis and molecular dynamics simulations
Abstract
Diabetes mellitus, one of the major health challenges of the 21st century, is associated with numerous biomedical complications including retinopathy, neuropathy, nephropathy, cardiovascular diseases and liver disorders. To control the chronic hyperglycemic condition, the development of potential inhibitors of drug targets such as α-glucosidase and α-amylase remains a promising strategy and focus of continuous efforts. Therefore, in the present work, a concise library of isobenzofuranone derivatives (3a-q) was designed and synthesized using Suzuki-Miyaura cross-coupling approach. The biological potential of these heterocyclic compounds against carbohydrate-hydrolyzing enzymes; α-glucosidase and α-amylase, was examined. In vitro inhibitory results demonstrated that the tested isobenzofuranones were considerably more effective and potent inhibitors than the standard drug, acarbose. Compound 3d having an IC50 value of 6.82 ± 0.02 μM was emerged as the lead candidate against α-glucosidase with ⁓127-folds strong inhibition than acarbose. Similarly, compound 3g demonstrated ⁓11-folds higher inhibition strength against α-amylase when compared with acarbose. Both compounds were tested in vivo and results demonstrate that the treatment of diabetic rats with α-amylase inhibitor show more pronounced histopathological normalization in kidney and liver than with α-glucosidase inhibitor. The Lineweaver-Burk plot revealed an uncompetitive mode of inhibition for 3d against α-glucosidase whereas compound 3g exhibited mixed inhibition against α-amylase. Furthermore, in silico molecular docking and dynamics simulations validated the in vitro data for these compounds whereas pharmacokinetics profile revealed the druglike properties of potent inhibitors.
Keywords: Diabetes; Heterocyclic drugs; In vivo activity; Molecular dynamics simulations; Suzuki-Miyaura cross-coupling; α-Amylase; α-Glucosidase.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Synthesis, in vitro and in vivo evaluation, and computational modeling analysis of thioxothiazolidine derivatives as highly potent and selective α-amylase inhibitors.Eur J Med Chem. 2025 Jul 5;291:117584. doi: 10.1016/j.ejmech.2025.117584. Epub 2025 Apr 1. Eur J Med Chem. 2025. PMID: 40220676
-
Discovery of new anti-diabetic potential agents based on paracetamol incorporating sulfa-drugs: Design, synthesis, α-amylase, and α-glucosidase inhibitors with molecular docking simulation.Eur J Med Chem. 2024 Sep 5;275:116589. doi: 10.1016/j.ejmech.2024.116589. Epub 2024 Jun 8. Eur J Med Chem. 2024. PMID: 38878516
-
Exploring chalcone-sulfonyl piperazine hybrids as anti-diabetes candidates: design, synthesis, biological evaluation, and molecular docking study.Mol Divers. 2025 Feb;29(1):43-59. doi: 10.1007/s11030-024-10831-x. Epub 2024 May 22. Mol Divers. 2025. PMID: 38775996
-
An insight on medicinal attributes of 1,2,3- and 1,2,4-triazole derivatives as alpha-amylase and alpha-glucosidase inhibitors.Mol Divers. 2024 Oct;28(5):3605-3634. doi: 10.1007/s11030-023-10728-1. Epub 2023 Sep 21. Mol Divers. 2024. PMID: 37733243 Review.
-
Flavonoids as potential agents in the management of type 2 diabetes through the modulation of α-amylase and α-glucosidase activity: a review.Crit Rev Food Sci Nutr. 2022;62(12):3137-3207. doi: 10.1080/10408398.2020.1862755. Epub 2021 Jan 11. Crit Rev Food Sci Nutr. 2022. PMID: 33427491 Review.
Cited by
-
Key molecular scaffolds in the development of clinically viable α-amylase inhibitors.Future Med Chem. 2025 Feb;17(3):347-362. doi: 10.1080/17568919.2025.2453421. Epub 2025 Jan 21. Future Med Chem. 2025. PMID: 39835704 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical